Skip to main content
Log in

Anti-VEGF monoclonal antibodies: risk of hypertension in cancer patients

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. vascular endothelial growth factor

Reference

  • Yin G, et al. Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. Journal of Chemotherapy : 1-14, 6 Jul 2021. Available from: URL: http://doi.org/10.1080/1120009X.2021.1947022

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-VEGF monoclonal antibodies: risk of hypertension in cancer patients. Reactions Weekly 1864, 6 (2021). https://doi.org/10.1007/s40278-021-98936-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-98936-6

Navigation